ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II cl…
Biotechnology
US, Winston-Salem [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 17.94 | 17.62 | 14.94 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -17.62 | 2.00 | 2.43 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 2.41 | -17.98 | -18.43 | |
| Cash | -10.95 | 5.40 | 6.06 | |
| Capex | 40.00 | -0.02 | -0.03 | |
| Free Cash Flow | -29.77 | -0.58 | -0.45 | |
| Revenue | inf | 0.00 | 0.08 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | inf | 0.00 | 0.77 | |
| Operating Margin | inf | 0.00 | -5.39 | |
| ROA | -80.58 | -0.02 | -0.01 | |
| ROE | 67.61 | < 0.005 | < 0.005 | |
| ROIC | 45.85 | 0.04 | 0.03 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of PROK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of PROK is permitted for members.
6
Leverage & Liquidity